Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2015 Nov;4(11):1639-50.
doi: 10.1002/cam4.504. Epub 2015 Aug 26.

Efficacy and safety of botulinum toxin type A for treatment of Frey's syndrome: evidence from 22 published articles

Shang Xie  1 , Kan Wang  1 , Tao Xu  1 , Xue-Sheng Guo  2 , Xiao-Feng Shan  1 , Zhi-Gang Cai  1
Affiliations
Meta-Analysis

Efficacy and safety of botulinum toxin type A for treatment of Frey's syndrome: evidence from 22 published articles

Shang Xie et al. Cancer Med. 2015 Nov.

Abstract

Frey's syndrome (FS) is an unavoidable sequela following the surgery of the parotid gland. Although several treatment methods are available, their efficacy is short term or accompanied by unacceptable complications. In the past two decades, botulinum toxin type A (BTXA) has been widely used to treat FS. Although several systematic reviews have been reported recently, they were conflicting and with obvious deficiencies. Thus, we performed an objectively systematic review to determine whether BTXA is an effective and safe treatment for FS. A literature retrieval covering PubMed, Web of Science, Ovid, Embase and Cochrane library was performed on 16 January, 2015. Proportion meta-analysis and corresponding 95% confidence interval (CI) were performed to evaluate the efficacy and safety of BXTA in treatment of FS. A total of 499 records were retrieved and 22 articles with 23 studies were included after scrutiny by two independent authors. Statistical analyses regarding the effective rate, incidence of complications were used to estimate the efficacy and safety of BTXA. Our results suggested that the effective rate of BTXA for treatment of FS is 98.5% (95% CI = 0.971-0.994) and the incidence of complication is 3.6% (95% CI = 0.017-0.061). In conclusion, our study supports that BTXA produces meaningful benefits on the treatment of patients with FS. However, owing to lack of strong evidence, future studies with well-designed inclusion criteria and multicenter randomized controlled trials are needed to give more credible evidence, if possible.

Keywords: Botulinum toxin type A; Frey's syndrome; efficacy; proportion meta-analysis; safety.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow diagram of the literature retrieval.
Figure 2
Figure 2
Effective rate of botulinum toxin type A in treatment of Frey’s syndrome (proportion meta-analysis).
Figure 3
Figure 3
Incidence of complications regarding of botulinum toxin type A in treatment of Frey’s syndrome (proportion meta-analysis).
See this image and copyright information in PMC

References

    1. May JS. McGuirt WF. Frey’s syndrome: treatment with topical glycopyrrolate. Head Neck. 1989;11:85–89. - PubMed
    1. Linder TE, Huber A. Schmid S. Frey’s syndrome after parotidectomy: a retrospective and prospective analysis. Laryngoscope. 1997;107:1496–1501. - PubMed
    1. Laage-Hellman JE. Treatment of gustatory sweating and flushing. Acta Otolaryngol. 1958;49:132–143. - PubMed
    1. Laskawi R, Schott T, Mirzaie-Petri M. Schroeder M. Surgical management of pleomorphic adenomas of the parotid gland: a follow-up study of three methods. J. Oral Maxillofac. Surg. 1996;54:1176–1179. - PubMed
    1. Bjerkhoel A. Trobbe O. Frey’s syndrome: treatment with botulinum toxin. J. Laryngol. Otol. 1997;111:839–844. - PubMed

Publication types

MeSH terms

Substances